
**Biological evaluation of medical
devices —**

**Part 22:
Guidance on nanomaterials**

*Évaluation biologique des dispositifs médicaux —
Partie 22: Lignes directrices sur les nanomatériaux*

Sample Document

get full document from standards.iteh.ai



Sample Document

get full document from standards.iteh.ai



COPYRIGHT PROTECTED DOCUMENT

© ISO 2017, Published in Switzerland

All rights reserved. Unless otherwise specified, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office
Ch. de Blandonnet 8 • CP 401
CH-1214 Vernier, Geneva, Switzerland
Tel. +41 22 749 01 11
Fax +41 22 749 09 47
copyright@iso.org
www.iso.org

Contents

Page

Foreword	v
Introduction	vi
1 Scope	1
2 Normative references	2
3 Terms and definitions	2
4 General principles	5
4.1 General considerations	5
4.2 Biological evaluation of nanomaterials	6
4.3 Categorization of nanomaterials	6
4.4 Nanomaterial equivalence	8
5 Characterization of nanomaterials	8
5.1 General considerations	8
5.2 Characterization parameters and methods	10
5.3 Use of reference materials	14
6 Sample preparation	15
6.1 General considerations	15
6.2 Special considerations for nanostructured materials	15
6.3 Special considerations for nano-objects	15
6.4 Identity, storage and stability of stock nanomaterials	17
6.5 Description of chemical composition of stock and dosing dispersions	17
6.6 Characterization of stock dispersions	18
6.7 Characterization of dosing solutions prepared from stock dispersions	18
6.8 Dose metrics	19
6.9 Additional considerations	19
6.9.1 Endotoxin	19
6.9.2 Sterilization	20
7 Release of nano-objects from medical devices	21
7.1 General considerations	21
7.2 Degradation products	22
7.3 Release of nano-objects by wear	22
7.4 <i>In situ</i> processing	22
8 Toxicokinetics	22
8.1 General considerations	22
8.2 Factors influencing the toxicokinetics	23
8.2.1 Physicochemical properties	23
8.2.2 Biomolecular adsorption	24
8.2.3 Exposure route	25
8.2.4 Dose	25
8.2.5 Species and gender	25
8.2.6 Measurement techniques	26
9 Toxicological evaluation	26
9.1 General considerations	26
9.2 <i>In vitro</i> cytotoxicity testing	27
9.2.1 General considerations	27
9.2.2 Consideration of nanomaterial interference with the assays	28
9.2.3 Consideration of relevant dose and dose metrics	28
9.2.4 Consideration of nano-object kinetics	28
9.3 Genotoxicity, carcinogenicity and reproductive toxicity	29
9.3.1 General considerations	29
9.3.2 <i>In vitro</i> genotoxicity tests	30
9.3.3 <i>In vivo</i> genotoxicity tests	31

9.3.4	Carcinogenicity.....	32
9.3.5	Reproductive toxicity.....	32
9.4	Immunotoxicity, irritation and sensitization.....	33
9.4.1	General considerations.....	33
9.4.2	Immunotoxicity.....	33
9.4.3	Sensitization.....	34
9.4.4	Irritation.....	35
9.5	Haemocompatibility.....	36
9.5.1	General considerations.....	36
9.5.2	Complement system activation.....	37
9.5.3	Specific considerations for haemocompatibility testing.....	37
9.6	Systemic toxicity.....	37
9.7	Pyrogenicity.....	38
9.8	Implantation.....	39
10	Presentation of characterization and test results.....	39
11	Risk assessment.....	40
11.1	General considerations.....	40
11.2	Exposure assessment.....	42
11.3	Biological hazard identification.....	43
11.4	Risk estimation.....	44
11.5	Risk evaluation.....	44
12	Biological evaluation report.....	44
	Bibliography.....	46

Sample Document

get full document from standards.iteh.ai

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see www.iso.org/patents).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation on the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT) see the following URL: www.iso.org/iso/foreword.html.

This document was prepared by Technical Committee ISO/TC 194, *Biological and clinical evaluation of medical devices*.

A list of all parts in the ISO 10993 series can be found on the ISO website.

Introduction

This document is intended as guidance for the biological evaluation of medical devices that contain, generate or are composed of nanomaterials. Multiple definitions have been developed for the term nanomaterial. For the purposes of this document, the ISO definition will be used: A material is considered a nanomaterial when it has a size at the nanoscale including external and internal dimensions, i.e. when it has a size or is composed of structures with a length of approximately between 1 nm and 100 nm (ISO/TS 80004-1:2015). For regulatory purposes, it is advisable to check if specific national or regional regulatory definitions are applicable. It should be realized that other characteristics (e.g. nanospecific properties) might also be included in such definitions.

Morphological structures created on the surface of a medical device can also have sizes in the nanoscale. Therefore, possible effects of such structures on the biological response to the device also need to be considered.

Nano-objects having a length range from 1 nm to 100 nm can be generated during the life cycle of a medical device, so the evaluation of possible adverse effects due to the generation of nano-objects either from preparation, use, wear or degradation of medical devices needs to be addressed. This applies to medical devices manufactured using nanomaterials and medical devices that are manufactured not using nanomaterials but having the potential to generate nanoscale wear and/or degradation particles. For the biological evaluation of medical devices, knowledge on the potential generation and/or release of nano-objects from such materials is essential.

The procedures as described in the ISO 10993 series for the biological evaluation of medical devices can be used for the biological evaluation of those medical devices that contain nano-objects that are not released from such a device as they are an integrated part of the device. However, when release of the nano-objects is possible, a safety evaluation should also be performed on the released nano-objects. In addition to evaluating a medical device, nanomaterial components or constituents can also be separately evaluated.

This document provides trained professionals, in the context of medical device evaluation, a general approach to biological evaluation of nanomaterials and addresses how the other parts of the ISO 10993 series can be used when dealing with the evaluation of nanomaterials. It is likely that the various assays as described in the ISO 10993 series are not always appropriate as such in the testing of nanomaterials. Nanomaterials by themselves can be present as powders or colloid dispersions, but also can be present in medical devices while incorporated in a matrix, as nanostructured material or as surface structures on materials and/or medical devices. In general, nanomaterials themselves need to be evaluated instead of extracts as usually used when testing biomaterials or medical devices. Nanomaterials pose specific challenges when applying test systems commonly used for medical device evaluation and when interpreting test results.

The field of nanotechnology, development of nanomaterials and the evaluation of potential toxicity of such materials are emerging fields and this document represents only the knowledge at the time of writing. Although appropriate tools and methods for evaluation of nanomaterials are still under development, data on the characteristics and biological effects of nanomaterials should be provided in order to address safety issues in their application in the medical device field, taking into consideration a risk/benefit analysis.

This document provides guidance on how to perform a biological evaluation for those medical devices that contain, generate, or are composed of nanomaterials within a risk management process as described in ISO 10993.

Biological evaluation of medical devices —

Part 22: Guidance on nanomaterials

1 Scope

This document describes considerations for the biological evaluation of medical devices that are composed of or contain nanomaterials. In addition, this guidance can also be used for the evaluation of nano-objects generated as products of degradation, wear, or from mechanical treatment processes (e.g. *in situ* grinding, polishing of medical devices) from (components of) medical devices that are manufactured not using nanomaterials.

This document includes considerations on the:

- characterization of nanomaterials;
- sample preparation for testing of nanomaterials;
- release of nano-objects from medical devices;
- toxicokinetics of nano-objects;
- biological evaluation of nanomaterials;
- presentation of results;
- risk assessment of nanomaterials in the context of medical device evaluation;
- biological evaluation report;
- nanostructures on the surface of a medical device, intentionally generated during the engineering, manufacturing or processing of a medical device.

The following are excluded from this document:

- natural and biological nanomaterials, as long as they have not been engineered, manufactured or processed for use in a medical device;
- intrinsic nanostructures in a bulk material;
- nanostructures on the surface of a medical device, generated as an unintentional by-product during the engineering, manufacturing or processing of a medical device.

NOTE Examples of unintentional nanostructures on the surface of a medical device are extrusion draw lines and machining/tool marks.

This document is intended to provide a general framework and highlights important aspects which need to be considered when assessing the safety of medical devices composed of, containing and/or generating nano-objects. Additionally, the document identifies several common pitfalls and obstacles which have been identified when testing nanomaterials compared to bulk materials or small molecule chemical species. As a technical report (TR), this document represents the current technical knowledge related to nanomaterials. No detailed testing protocols are outlined or provided. This document can serve as a basis for future documents containing detailed protocols with a focus on nanomaterial testing.

2 Normative references

The following documents are referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 10993 (all parts), *Biological evaluation of medical devices*

ISO/TR 13014, *Nanotechnologies — Guidance on physico-chemical characterization of engineered nanoscale materials for toxicologic assessment*

ISO 14971, *Medical devices — Application of risk management to medical devices*

3 Terms and definitions

For the purposes of this document, the terms and definitions given in ISO 10993 (all parts), ISO/TR 13014 and ISO 14971 and the following apply.

ISO and IEC maintain terminological databases for use in standardization at the following addresses:

- ISO Online browsing platform: available at <http://www.iso.org/obp>
- IEC Electropedia: available at <http://www.electropedia.org/>

3.1
aggregate
particle comprising strongly bonded or fused particles where the resulting external surface area is significantly smaller than the sum of calculated surface areas of the individual components

Note 1 to entry: The forces holding an aggregate together are strong forces, for example, covalent bonds, or those resulting from sintering or complex physical entanglement.

Note 2 to entry: Aggregates are also termed secondary particles and the original source particles are termed primary particles.

[SOURCE: ISO/TS 80004-2:2015, 3.5, modified — definition and Note 1 to entry changed]

3.2
agglomerate
collection of weakly bound particles or *aggregates* (3.1) or mixtures of the two where the resulting external surface area is similar to the sum of the surface areas of the individual components

Note 1 to entry: The forces holding an agglomerate together are weak forces, for example van der Waals forces, or simple physical entanglement.

Note 2 to entry: Agglomerates are also termed secondary particles and the original source particles are termed primary particles.

[SOURCE: ISO/TS 80004-2:2015, 3.4]

3.3
engineered nanomaterial
nanomaterial (3.7) designed for a specific purpose or function

[SOURCE: ISO/TS 80004-1:2015, 2.8]

3.4
incidental nanomaterial
nanomaterial (3.7) generated as an unintentional by-product of a process

Note 1 to entry: The process includes manufacturing, bio-technological or other processes.

Note 2 to entry: See “ultrafine particle” in ISO/TR 27628:2007, 2.21.

[SOURCE: ISO/TS 80004-1:2015, 2.10]

3.5

manufactured nanomaterial

nanomaterial (3.7) intentionally produced to have selected properties or composition

[SOURCE: ISO/TS 80004-1:2015, 2.9]

3.6

nanofibre

nano-object (3.8) with two similar external dimensions in the *nanoscale* (3.12) and the third dimension significantly larger

Note 1 to entry: A nanofibre can be flexible or rigid.

Note 2 to entry: The two similar external dimensions are considered to differ in size by less than three times and the significantly larger external dimension is considered to differ from the other two by more than three times.

Note 3 to entry: The largest external dimension is not necessarily in the nanoscale.

[SOURCE: ISO/TS 80004-6:2013, 2.6]

3.7

nanomaterial

material with any external dimension in the *nanoscale* (3.12) or having internal structure or surface structure in the nanoscale

Note 1 to entry: This generic term is inclusive of *nano-object* (3.8) and *nanostuctured material* (3.17).

Note 2 to entry: See also 3.3 to 3.5.

Note 3 to entry: For regulatory purposes, it is advisable to check if specific national or regional regulatory definitions are applicable. It should be realized that different size ranges or other properties might be included in such definitions.

[SOURCE: ISO/TS 80004-1:2015, 2.4, modified — Note 2 to entry modified and Note 3 to entry added]

3.8

nano-object

discrete piece of material with one, two or three external dimensions in the *nanoscale* (3.12)

Note 1 to entry: The second and third external dimensions are orthogonal to the first dimension and to each other.

[SOURCE: ISO/TS 80004-1:2015, 2.5]

3.9

nanoparticle

nano-object (3.8) with all external dimensions at the *nanoscale* (3.12) where the length of the longest and the shortest axes of the nano-object do not differ significantly

Note 1 to entry: If the dimensions differ significantly (typically by more than 3 times), terms such as *nanofibre* or *nanoplate* may be preferred to the term nanoparticle.

[SOURCE: ISO/TS 80004-2:2015, 4.4]

3.10

nanoplate

nano-object (3.8) with one external dimension in the *nanoscale* (3.12) and the two other external dimensions significantly larger

Note 1 to entry: The smallest external dimension is the thickness of the nanoplate.

Note 2 to entry: The two significantly larger dimensions are considered to differ from the nanoscale dimension by more than three times.

Note 3 to entry: The larger external dimensions are not necessarily in the nanoscale.

[SOURCE: ISO/TS 80004-6:2013, 2.4]

**3.11
nanorod**

solid *nanofibre* (3.6)

[SOURCE: ISO/TS 80004-2:2015, 4.7]

**3.12
nanoscale**

length range approximately from 1 nm to 100 nm

Note 1 to entry: Properties that are not extrapolations from larger sizes are predominantly exhibited in this length range.

Note 2 to entry: Properties impacting biocompatibility can also occur at larger sizes, e.g. between 100 nm and 1 µm.

[SOURCE: ISO/TS 80004-1:2015, 2.1, modified — Note 2 to entry was added]

**3.13
nanoscale phenomenon**

effect attributable to the presence of *nano-objects* (3.8) or *nanoscale* (3.12) regions

[SOURCE: ISO/TS 80004-1:2015, 2.13]

**3.14
nanoscale property**

characteristic of a *nano-object* (3.8) or *nanoscale* (3.12) region

[SOURCE: ISO/TS 80004-1:2015, 2.14]

**3.15
nanoscience**

study, discovery and understanding of matter, where size- and structure-dependent properties and phenomena manifest, predominantly in the *nanoscale* (3.12), distinct from those associated with individual atoms or molecules, or extrapolation from larger sizes of the same material

[SOURCE: ISO/TS 80004-1:2015, 2.2]

**3.16
nanostructure**

composition of inter-related constituent parts in which one or more of those parts is a *nanoscale* (3.12) region

Note 1 to entry: A region is defined by a boundary representing a discontinuity in properties.

[SOURCE: ISO/TS 80004-1:2015, 2.6]

**3.17
nanostructured material**

material having internal *nanostructure* (3.16) or surface nanostructure

Note 1 to entry: This definition does not exclude the possibility for a *nano-object* (3.8) to have internal structure or surface structure. If external dimension(s) are in the *nanoscale* (3.12), the term nano-object is recommended.

[SOURCE: ISO/TS 80004-1:2015, 2.7]

3.18**nanotechnology**

application of scientific knowledge to manipulate and control matter predominantly in the *nanoscale* (3.12) to make use of size- and structure-dependent properties and phenomena distinct from those associated with individual atoms or molecules, or extrapolation from larger sizes of the same material

Note 1 to entry: Manipulation and control includes material synthesis.

[SOURCE: ISO/TS 80004-1:2015, 2.3]

3.19**nanotube**

hollow *nanofibre* (3.6)

[SOURCE: ISO/TS 80004-2:2015, 4.8]

3.20**representative test material****RTM**

material, which is sufficiently homogenous and stable with respect to one or more specified properties, and is implicitly assumed to be fit for its intended use in the development of measurement and test methods that target properties other than those for which homogeneity and stability have been demonstrated

[SOURCE: ISO/TS 16195:2013; 3.1, modified — Notes 1 and 2 to entry deleted]

4 General principles**4.1 General considerations**

Nanomaterials are manufactured and used because of the specific properties that can be associated with the decrease in size accompanied by an increase of surface area. Also, materials with dimensions in the size range >100 nm or <1 micron can elicit properties different from those in the macroscale (>1 micron). For these types of particulate materials, it might be considered to perform an assessment similar to nanomaterials in the size range between 1 nm and 100 nm.

The biological evaluation of any material or medical device intended for use in humans should form part of a structured biological evaluation program within a risk management process in accordance with ISO 14971 and ISO 10993-1. The risk management process is applicable to devices that contain or are composed of nanomaterials. The risk management process is also applicable to devices that generate nano-objects as products of degradation, wear, or from mechanical treatment processes (e.g. *in situ* grinding, polishing of medical devices). Similarly, if there is release of nano-objects, there are specific challenges in the safety evaluation of such products. The safety evaluation and risk assessment of nanomaterials requires a special focus as various nanomaterials consisting of the same chemical substance can have a different toxicological risk profile depending on a number of variables, including size, surface chemistry, physicochemical properties and intended application. For medical devices that are composed of or that contain nanomaterials, the safety evaluation program should specifically address issues related to the safety evaluation of nanomaterials. The ISO 10993 series, ISO/TR 13014, ISO 14971, and References [5],[14],[15],[16],[21],[23],[24],[28],[46],[47] and [49] deal with biological evaluation of medical devices and various aspects of nanomaterials.

Nanomaterials have sizes similar to structures at subcellular levels including DNA, and thus (theoretically) can reach and interact with such structures. Also, medical devices utilizing materials with nanoscale internal structures or with surface nanoscale features associated with coatings, functionalization, or with other topographical features on the nanoscale, that are intended as part of the functionality of the device, can have specific and unique properties that might need to be addressed in the biological evaluation. For example, it has been shown that nanoscale surface topography can influence cell alignment, cell morphology, cell signalling, gene expression and extracellular matrix [52] [53] [54].

The release of nano-objects and the use of free nanomaterials are considered to pose the highest potential for risk in view of the potential internal exposure that can occur.

4.2 Biological evaluation of nanomaterials

ISO 10993-1:2009, Annex A, provides a framework for the development of an assessment program of the biological risks that should be considered depending upon a device's type and duration of body contact. This framework is also generally applicable to devices that contain, generate or are composed of nanomaterials. Such testing should be based on each device's merits. Special considerations apply to the ISO 10993 series of tests due to the presence of nanomaterials, as outlined in this document.

ISO 10993-1 provides guidance on the risk management process, which includes hazard identification, exposure assessment and risk estimation. This process is generally sufficiently robust and flexible to provide a basis for evaluation of nanomaterials, even though they can have properties that can be different from conventional ones. This process, including biological evaluation strategy, program content and acceptance criteria of the risk related to the nanomaterials as required by ISO 10993-1, should be planned, carried out and documented by knowledgeable and experienced professionals. The initial step in the biological evaluation of nanomaterials is to gather existing information on that particular nanomaterial according to the general approach as described in ISO 10993-1. Literature review of clinical and non-clinical data should be carried out according to ISO 10993-1:2009, Annex C to provide a rigorous and objective summary of available information about the nanomaterial and its intended application. Reference [55] has summarized several places where information about nanomaterials can be found. Following the logic of ISO 14971 and ISO 10993-1, if the biological safety assessment concludes from existing data that the identified risks are acceptable, no further testing is needed. Otherwise, additional information should be obtained. In order to use existing data for the biological evaluation, demonstration of nanomaterial equivalence is necessary (see 4.4).

4.3 Categorization of nanomaterials

The exposure assessment and hazard identification should be based on the characteristics of the finished medical device and the intended use. Hazard identification should consider the physicochemical and toxicological properties of the nanomaterial, including additives and processing aids. Exposure assessment should consider the concentration of nanomaterial used in the medical device, intended use and exposure route, and the rate and pattern of release and estimated patient exposure. The manner in which the nanomaterial is incorporated into the finished medical device can significantly alter the exposure characteristics[56]. General considerations for different categories of nanomaterials and medical devices are presented in Table 1. Certain devices might fall into more than one category, in which case evaluation appropriate to each category should be considered. The evaluation of any device that does not fall into one of the categories described should follow the general principles contained in ISO 10993-1, along with any special considerations outlined within this document.

Table 1 — Considerations for biological evaluation of medical devices that contain, generate, or are composed of nanomaterials

Category ^a	Type of nanomaterial in the medical device	Considerations in addition to the biological evaluation according to ISO 10993-1
1	Surface nanostructures	— Consider potential cellular or tissue effects due to direct interaction with surface nanostructures (beneficial or adverse). — Consider potential of structures to be released (break off) from the surface. — Consider potential of nano-objects to be generated by degradation, wear or mechanical treatment processes. — Consider characterization of nanostructures (see Clause 5).
2	Nano-objects bound to or incorporated within a medical device; without intention to be released	— Consider potential cellular or tissue effects due to direct interaction with surface-bound nano-objects/nano-materials (beneficial or adverse). — Consider potential of nano-objects to be released from the device. — Consider potential of nano-objects to be generated by degradation, wear or mechanical treatment processes. — Consider characterization of physicochemical properties of the nano-objects (see Clause 5).
3	Nano-objects/nanostructures on the surface of or within a medical device; with intentional/expected release from the device	— Consider release kinetics (rate and quantity) of the nano-objects and contact duration of the medical device. — Consider potential cellular or tissue effects due to direct interaction with nano-objects/nanomaterials (beneficial or adverse). — Consider characterization of physicochemical properties of the released nano-objects (see Clause 5). — Consider toxicokinetics and tissue distribution of the nano-objects (see Clause 8). — Consider biological evaluation of the nano-objects (see Clause 9). — Consider potential of nano-objects to be generated by degradation, wear or mechanical treatment processes.
4	Nano-object medical device	— Consider characterization of physicochemical properties of the nano-objects (see Clause 5). — Consider toxicokinetics and tissue distribution of the nano-objects (see Clause 8). — Consider biological evaluation of the nano-objects (see Clause 9).
^a A device can contain nanomaterials in more than one category. ^b Nano-objects can be generated from a medical device that does not contain nano-objects. ^c Degradation, wear or treatment of a medical device containing nano-objects can generate new or unintended nano-objects.		

Table 1 (continued)

Category ^a	Type of nanomaterial in the medical device	Considerations in addition to the biological evaluation according to ISO 10993-1
5	Nano-objects ^b released from a medical device as product of degradation, wear, or from mechanical treatment ^c processes (e.g. <i>in situ</i> grinding or polishing)	— Consider characterization of physicochemical properties of the nano-objects (see Clause 5). — Clause 7 describes additional considerations for nano-objects released by wear or generated by <i>in situ</i> processing. — Consider toxicokinetics and tissue distribution of the nano-objects (see Clause 8). — Consider biological evaluation of the generated nano-objects (see Clause 9). — Consider contact duration and release kinetics (rate and quantity).
^a A device can contain nanomaterials in more than one category. ^b Nano-objects can be generated from a medical device that does not contain nano-objects. ^c Degradation, wear or treatment of a medical device containing nano-objects can generate new or unintended nano-objects.		

4.4 Nanomaterial equivalence

Proper identification and characterization of the nanomaterial is essential. For nanomaterials, equivalence is dependent on multiple factors. Chemical composition alone is not sufficient to demonstrate equivalence as nanomaterial-specific properties can also be influenced by a number of other factors such as size, shape and surface properties of the nanomaterial and/or the source (manufacturer) of these nanomaterials, manufacturing process and storage conditions. Equivalence can only be claimed if properly demonstrated and justified by accompanying data.

In general, extrapolation of results by using existing data from other products using/containing similar nanomaterials, or from the corresponding parent compound of the same substance is not applicable, although such products can give an indication of possible safety concerns. If testing is considered necessary, it should be performed on the actual product and/or any nanomaterials which can come into contact with patients.

5 Characterization of nanomaterials

5.1 General considerations

Knowledge of the physicochemical properties of nanomaterials is essential to understanding their behaviour in biological systems. The physicochemical characterization is necessary for the identification of a specific nanomaterial. Characterization of the physicochemical properties of nanomaterials/nano-objects incorporated in a device and/or created by degradation, wear or mechanical treatment processes of the device is thus an important step in completing its biological evaluation. Physicochemical characterization can also be useful in the screening of potential new nanomaterials for suitability in a medical device for a proposed application. In addition, a proper characterization is necessary to establish or confirm the specifications of a nanomaterial in a defined medium and conditions.

Physicochemical characterization addresses three fundamental questions about a nanomaterial used in or released from a medical device.

- **Chemical composition:** What is it made of?
- **Physical description:** What does it look like?
- **Extrinsic properties:** How does it interact with the surrounding environment?

The physicochemical properties associated with these questions encompass a wide range of nano-object characteristics. In keeping with guidance for evaluation of conventional materials used in medical devices, the physicochemical characterization of nano-scaled materials is targeted to properties that are relevant to the biological evaluation and the intended use of the device (clinical application and duration of use). General principles for chemical, physicochemical, morphological and topographical characterization of materials used in medical devices are covered in ISO 10993-18 and ISO/TS 10993-19. The identification and quantification of degradation products in medical devices are addressed in ISO 10993-9, ISO 10993-13, ISO 10993-14 and ISO 10993-15. Detailed guidance specifically for the physicochemical characterization of nanomaterials is emerging. Recently published guidance includes ISO/TR 13014 and ISO/TR 14187 and guidances published by the European Commission for food and feed, cosmetic ingredients and medical devices^[57] ^[58] ^[59].

ISO/TR 13014 lists the following as properties of engineered nanomaterials to be characterized in the context of toxicological testing:

- chemical composition;
- purity;
- object size and size distribution;
- aggregation and agglomeration state;
- shape;
- surface area;
- surface chemistry;
- surface charge;
- solubility;
- dispersibility.

These properties should be viewed as a starting point for the evaluation of nanomaterials used in a device; characterization of additional properties might be indicated depending on the design, intended use and wear characteristics of the device. Examples of other physicochemical properties that might be considered on a case-by-case basis include:

- crystallinity;
- porosity;
- redox potential;
- (photo)catalysis;
- radical formation potential;
- octanol/water partition coefficient (might not be applicable for solid materials).

In order to obtain the required data as indicated above, multidisciplinary collaborations among toxicologists, physical chemists, engineers and other subject-area experts are necessary in developing a relevant and reliable characterization program for a specific nanomaterial containing device.

Specific guidance for characterization is available for certain nanomaterials, e.g. single and multiwall carbon nanotubes (SWCNT, MWCNT), nanoscale calcium carbonate powder, nanoscale titanium dioxide powder, gold and silver nanoparticles, and nanoclays¹⁾.

1) For details, see http://www.iso.org/iso/home/store/catalogue_tc/catalogue_tc_browse.htm?commid=381983.